Showing posts with label Weldon. Show all posts
Showing posts with label Weldon. Show all posts

Monday, March 20, 2017

Risperdal Lawsuits Contribute To Johnson & Johnson's Legal Costs

prnewswire

News provided by Bernstein Liebhard LLP

Mar 13, 2017, 11:36 ET

NEW YORK, March 13, 2017 /PRNewswire/ -- Johnson & Johnson's legal costs grew by 480% last year, as Risperdal lawsuits and legal claims involving a number of other products continued to mount in 2016. According to a report that recently appeared in the Financial Times, more than 107,000 product liability claims were pending against Johnson & Johnson by the start of 2017, including more than 28,000 that were filed in 2016. Over 18,000 of the pending cases involve Risperdal, including many that allege the antipsychotic drug caused men and boys to develop gynecomastia, a condition marked by the growth of female-like breasts.

"Over the past several years, we have heard from numerous individuals interested in pursuing Risperdal gynecomastia claims, and our Firm still receives inquiries from prospective plaintiffs on a fairly regular basis. We are not at all surprised that this litigation continues to contribute to Johnson & Johnson's litigation costs," said Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm continues to provide free legal reviews to men and boys who allegedly experienced excessive breast growth due to their use of the antipsychotic medication.

Risperdal Litigation

Risperdal is an atypical antipsychotic drug currently indicated to treat certain psychiatric disorders in adults and children. It was brought to market in the early 1990s, and received U.S. Food & Drug Administration (FDA) approval for its first pediatric indications in 2006. Plaintiffs pursuing Risperdal lawsuits over gynecomastia claim that Johnson & Johnson and its Janssen Pharmaceuticals unit concealed data linking its use to excessive male breast growth, and failed to provide doctors and patients with appropriate warnings regarding this risk. They also claim that the companies wrongly marketed Risperdal to treat children long before U.S. regulators approved the drug for any pediatric uses.

Risperdal litigations are underway in a number of state courts, including Missouri, New Jersey and Pennsylvania. Over the past two years, the mass tort program established for Risperdal lawsuits in the Philadelphia Court of Common Pleas has convened a number of trials. Several have concluded with verdicts in favor of plaintiffs, with judgments ranging from $500,000 to $70 million. Confidential Risperdal settlements have also been reached in some cases just prior to trial. (In Re: Risperdal Litigation, Case ID: 100300296)

Risperdal patients who experienced the growth of female-like breasts while using the medication may be able to pursue a lawsuit of their own. To learn more, please contact Bernstein Liebhard LLP by visiting the Firm's website, or by calling 800-511-5092.

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's "Plaintiffs' Hot List," recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2017 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
info (at)consumerinjurylawyers (dot)com
http://www.rxinjuryhelp.com/
https://plus.google.com/115936073311125306742?rel=author

SOURCE Bernstein Liebhard LLP
Related Links http://www.bernlieb.com



Thank You PR Newswire and Bernstein Liebhard LLP.


Mental Health: Comes With FREE Sudden Death


Or as PhARMA's bagmen - the FDA - puts it:  

Hard At Work Speeding Approval of New Life Saving Medications.

FDA Commissioner Margaret Hamburg Named In Racketeering Lawsuit: Alleged  Conspiracy With JNJ To Increase Profits

"Former Food and Drug Administration (FDA) Commissioner Margaret A. Hamburg, her hedge-fund executive husband, and Fortune 500 giant Johnson & Johnson colluded to enrich themselves by failing to warn the public about a “deadly” antibiotic, a federal racketeering lawsuit claims.

Once confirmed as FDA commissioner, Dr. Margaret A. Hamburg acted as the instrumentality that all defendants used to perpetrate their conspiracy and racketeering enterprise by having her act illegally and outside the scope of her authority as FDA commissioner to suppress material information to plaintiffs and the public that Levaquin was inherently dangerous and in fact, deadly,” the complaint alleges.

The suit was filed in the U.S. District Court for the District of Columbia Jan. 19, 2016, on behalf of five individuals who claim they suffered severe physical harm as a result of taking the antibiotic."

Monday, January 11, 2016

SCOTUS Denies J&J's Final Appeal of South Carolina Risperdal Verdict: PAY UP, $124 Million

fiercepharma
January 11, 2016 | By 


Johnson & Johnson ($JNJ) fell short Monday in its final effort to escape a Risperdal marketing penalty in South Carolina. The U.S. Supreme Court declined to take up J&J's last appeal in the case, putting the company on the hook for a $124 million penalty.

J&J had cited the Eighth Amendment in arguing against the penalty, saying it qualified as an "excessive fine." As Reuters notes, the U.S. Chamber of Commerce had backed the drugmaker in seeking Supreme Court review.

J&J's Janssen unit has been fighting South Carolina's deceptive trade practices court win since 2011, when a jury ordered the drugmaker to pay $327 million for Risperdal marketing violations. The company succeeded in lowering the judgment twice, first to $136 million and then, last year, to the final $124 million.

The lawsuit centered on promotional materials Janssen used to market the antipsychotic drug. Key to the case was a letter sent to South Carolina physicians, which overstated Risperdal's benefits compared with other drugs in its class and downplayed side effects, the jury found. The trial court judge ordered Janssen to pay about $4,000 for each of the more than 7,000 letters mailed.

The original $327 million judgment dwarfed other similar rulings in drug-marketing lawsuits, including sizable decisions and settlements in other Risperdal-related litigation, but it fell far short of a $1.2 billion verdict in Arkansas. The Arkansas Supreme Court struck down that judgment in March 2014, and the company later negotiated a settlement of $7.5 million.

The South Carolina decision survived that state's top court in a ruling last year, in which Justice John Kittredge backed the decision at trial, but lowered the $327 million penalty to $136 million.
In affirming the judgment against the company, Kittredge echoed the trial judge's "profit-at-all-costs" characterization of Janssen's marketing efforts. "Janssen's desire for market share and increased sales knew no bounds, leading to its egregious violation of South Carolina law," Kittredge wrote in the February 2015 ruling.

Janssen had argued that it did not intentionally deceive doctors with the now-notorious "Risperdal letter" that has featured in several state-court lawsuits. The drugmaker also contended that South Carolina's attorney general didn't prove patients were actually harmed by the drug. It was on that point that Kittredge lowered the judgment.

The "Risperdal letter" lawsuits compose only part of the mountain of litigation J&J has fought over the antipsychotic drug. The company agreed to pay $2.2 billion in a marketing settlement with the U.S. Justice Department and a group of states.

And the litigation isn't over yet. The company now faces more than 1,000 lawsuits over Risperdal's ability to trigger breast development in boys. J&J lost the first court battle last February, as a Philadelphia jury ordered J&J to pay almost $2.5 million to a young man who developed breasts while using Risperdal. In November, another jury awarded $1.75 million in a similar case.
- see the Reuters story


Thank You Ms Staton and Fierce Pharma.



J&J had cited the Eighth Amendment in arguing against the penalty, saying it qualified as an "excessive fine." 

Un real. J&J crying about the 8th Amendment. 


but Tardive Dyskinesia isn't excessive, nor does it constitute Cruel and Unusual Punishment, for committing a thought crime.

Sunday, November 15, 2015

J&J Recieves Slap On The Hand While Employees Soar, Despite Association With Risperdal

The Legal Examiner

Posted by Eric Terry
October 7, 2015 11:08 AM

According to America’s Most Admired Lawbreaker, a special report published in the Huffington Post, Johnson & Johnson (J&J) has never come forward with information that any of its employees were disciplined or fired for illegally promoting the antipsychotic drug Risperdal.
On the contrary, many current and former J&J employees associated with Risperdal have risen dramatically up the ranks and profited from the drug, in one way or another:
  • Alex Gorsky, who once managed the marketing of Risperdal, is now the company’s chairman and chief executive officer. He received a 48 percent raise, to $25 million annually in 2014; one year after the J&J settlement with the government was reached.
  • Gahan Pandina, the J&J executive who led the Risperdal roll-out in North America, is now the senior director and venture leader at Janssen Research & Development.
  • Ramy Mahmoud, who developed a children and adolescents business plan for Risperdal in 2001, earned a series of promotions with J&J before leaving to become president and chief operating officer at startup OptiNose, whose website notes that he participated in the “development, launch, and/or commercialization of dozens of pharmaceutical and medical device products spanning multiple therapeutic categories, including blockbusters such as Risperdal.”
  • Carin Binder, the executive who spearheaded publication of a “re-done” study that minimized the link between boys who took Risperdal and gynecomastia in the Journal of Child Psychiatry, became the medical affairs director of J&J before retiring in 2014.
Although Johnson & Johnson pleaded guilty and was fined more than $2 billion for aggressively marketing the antipsychotic drug Risperdal to the elderly and young boys, the penalty was little more than a drop in the bucket compared to the $30 billion brought to J&J through the worldwide sales of the medication.
The shocking story about actions taken by “The Credo Company,” the biggest company in the US’s most profitable industry, is worth a read and/or listen.  Johnson & Johnson made decisions  to illegally promote Risperdal to children and the elderly and cover up the side effects related to these individuals while making billions of dollars and these actions effect real people.  It should anger all individuals that this kind of power can go unchecked for so long by a company of this magnitude and with this kind of power.
There are currently 4,200 Risperdal claims on dockets across the U.S., according to a recent J&J Security and Exchange Commission (SEC) filing and these cases continue to be filed.

Thank You Mr. Terry and Legal Examiner.

These people should be on the wall at your post office.

Friday, September 18, 2015

America's Most Admired Law Breaker: Johnson And Johnson, and Risperdal

Steven Brill at the Huffington Post is publishing a new, multi installment expose of Johnson & Johnson, and their chemical brain eater, Risperdal

America's Most Admired Lawbreaker.
Nice to see Someone hasn't swept them under the rug the way Eric 'Fast and Furious Critics Can Kiss My Ass' Holder did.


J&J Risperdal Agrees To Pay Obama DOJ's Parking Ticket

These people and their garbage drug are not last years story. 

If our MSM had a scintilla of integrity they'd be all over this company, its entire supply chain, and its street pushers like stink on a bum.


Saturday, August 29, 2015

Building An Islamic State In America: One Church At A Time

No big. Just Deal With It. If you're bigoted enough to even notice it, much less be upset with the clowns responsible for it, the PFOPC (protected friends of political clowns) have got just what you need, whether you want it or not.

Just ask JNJ/Risperdal's Bill Weldon and Alex Gorsky.

And there's nothing that should upset you about their being protected either.


They've got Exactly what you and your kids need.

You thought criminal, you.

frontpagemag

Daniel Greenfield

Churches fall, mosques rise.

Daniel Greenfield, a Shillman Journalism Fellow at the David Horowitz Freedom Center, is a New York writer focusing on radical Islam.
Across Europe, thousands of churches have closed and many of them have become mosques. The St. Mark’s Cathedral in London survived Nazi bombers in WW2, but fell to a new invasion and became the New Peckham Mosque. In France, where there are now more Muslims than practicing Catholics, the Islamic colonists demanded that thousands of empty churches be turned into mosques. The Capernaum Church in Germany has become the Al-Nour Islamic Center. In Amsterdam, the St. Ignatius Church was transformed into the Fatih Camii Mosque. Its name means ‘The Conqueror’s Mosque’.
The original Fatih Camii Mosque had been built by the Turkish invaders in Constantinople on the site of the Church of the Holy Apostles. Like their ISIS descendants, the Turks drove out the Greek Christians, destroyed the church and replaced it with a mosque named after the monster Mehmed II, who inaugurated Islamic rule over the fallen city with slavery, rape and beheadings in the ISIS style.
Today ‘Conqueror’s Mosques’ have sprung up not only in Istanbul and Amsterdam, but in Paris, Toronto, Melbourne and Brooklyn, where within sight of the Statue of Liberty extending her torch of freedom to the oppressed of the world, stands the grim squalid outpost of the oppressor of the world.
Mehmed and the Statue of Liberty, the armies of Islam and our way of freedom cannot long coexist.
Islam is conquering Europe. It is also conquering America.
In Syracuse, New York, the Holy Trinity Catholic Church has become a mosque. Despite the church being protected by the Landmark Preservation Board, its crosses were cut down and painted over. After the Islamic terror attacks of September 11, no more planes flew into buildings. Instead they landed at airports disgorging a different sort of conquering army that came with visas instead of boxcutters.
In the decade after 9/11, the number of Muslims in Onondaga County more than doubled.  A key role was played by Catholic Charities of Onondaga County, which could not find the money and energy to maintain a church into which generations of immigrations had poured their hopes and dreams, but which served as one of the VOLAGs (voluntary agencies) filling the area with UNHCR approved refugees.
 75% of the “refugees” colonizing Syracuse are Muslim. Almost a thousand refugees a year are inflicted on the people of Syracuse who already live in the 23rd poorest city out of the 575 biggest cities in the country. Half the children of Syracuse live in poverty. But each refugee means a $725 check for the VOLAG. Last year that meant a $3 million grant for Catholic Charities.
And while VOLAGs like Catholic Charities cater to migrants, churches are turned into mosques. The North Side, where Catholic Charities has been active in its “charity work” is now full of women in hijabs and the Holy Trinity Church is no more.
Yusuf Soule, who bought the church, explained why he chose it. “The North Side is the magnet for refugees.  The two agencies that work with refugees (InterFaith Works and Catholic Charities) are here.”
The more of these magnets we create, the fewer churches and synagogues there will be. Temple Beth El in Syracuse was hit by a Muslim terrorist who set fire to it while shouting, “I did this for you, Allah.”
No one had to set the Holy Trinity Church on fire. The Conference of Catholic Bishops took care of that.
Civilizations don’t fall because there are barbarians at the gate. There are barbarians at the gate because a dying civilization has lost touch with the values that made it great. The barbarians didn’t bring down Byzantium. They aren’t bringing down America and Europe. The barbarians of the prophet just show up to profit from the fall and we are the ones who open the gates and hand over the keys to our killers.
Islam is built on the bones of civilizations. Every Islamic mosque is a conqueror’s mosque.
The most thrilling experience for the new colonizers of the West is the taking of a church or a synagogue and transforming it into a mosque. While for the moment this has to be done legally, it is the closest thing to the ISIS experience that an Islamist can have in America or Europe without going to jail.
 This tragedy isn’t only happening in Europe. As the events in Syracuse show, it is taking place right here.
And it isn’t only Catholic churches in New York that are falling victim to this new breed of immigrant Taliban demolishing the un-Islamic to make way for the Islamic.
Two Baptist churches in Louisville, Kentucky have been turned into mosques.
“On a trip to England a few years ago, I recall seeing dozens of churches that had become mosques and wondering how it could happen there; now it’s happening here,” Paul Chitwood, the executive director of theKentucky Baptist Convention, said.
Louisville has the misfortune of being a “preferred resettlement site” which makes it a major dumping ground. The Syrians are on their way courtesy of Islamic Relief USA and it already has 1,605 Somalis and plenty of Iraqis too.
Churches are being turned into mosques all across America. The Abundant Life Family Church in Nebraska is now the Sabah Mosque. St. John’s Catholic Church in Minneapolis became the Darul-Uloom Islamic Center. In Detroit, Our Lady Help of Christians Church fell to the Islamic Center of North Detroit.
Slowly and quietly, this is happening all across America as the Immigration Jihad uses taxpayer money to accomplish what Mohammed, Al Qaeda and ISIS could not. Al Qaeda can destroy our buildings, but only our government can import Muslim colonists who will take over them as bases for their ideology.
Back in Istanbul, Erdogan’s Islamist regime continues pressing to convert churches into mosques, completing the original work of the Caliphate before it was aborted by secular reformers.
 Erdogan had made his agenda clear when he recited the Islamist poem proclaiming, “The minarets are our bayonets, the mosques are our barracks, the believers are our soldiers”.  And so it has ever been.
The secular West is being swiftly Islamized. Vacant churches become mosques. The barracks of Islam fill with believers who batten on the hate and go out one day to behead a soldier or shoot up a recruiting office. Minarets hatefully thrust their bayonets at the sky warning of a larger war to come.
The Immigration Jihad is colonization plain and simple. It is a war of birth rates and beliefs. A West whose elites have lost their faith is unable to come to terms with the fact that the East has not. The mosques are not “additions to the community”, they are outposts of a hostile civilization whose faith is in the destruction of the West. ISIS or the Muslim torching a synagogue while crying, “I did this for you, Allah” are all part of one terrible arc of theological destruction.
In Mosul, the Syrian Orthodox Church of St Ephraim has been captured by ISIS and turned into a mosque. While we bemoan the barbarisms of ISIS, we are assembling its building blocks right here in our cities. Churches become mosques. Beheadings and horrible acts of terrorism take place monthly.
Our leaders refuse to put the pieces together. They refuse to understand what the flow of Muslim recruits from America to ISIS means and what the transformation of churches into barracks and bayonets means. They refuse to understand that they are helping to build an Islamic State in America. 
 Tags: ChurchIslammosques
Thank You Mr Greenfield and FPM

Thursday, June 27, 2013

20 Highest Paid Biopharma CEOs of 2012

Fierce Pharma has;
20 Highest Paid Biopharma CEOs of 2012
by Tracy Staton


Call it a rite of spring. Every year about this timeFiercePharma takes a look at executive compensation in the industry, and we rank the highest-paid CEOs. If you're a regular reader, you'll notice that this year's list is longer than previous editions. And there's a reason for that: curiosity.

As we were beginning to gather numbers from biopharma companies' proxy statements and annual reports, news surfaced that Valeant Pharmaceuticals ($VRX) and Actavis ($ACT) had been in merger talks. The former CEO of Mylan ($MYL), one of Actavis' rivals, regularly appeared on our highest-paid executives list, so we looked up the numbers on Actavis. No dice; CEO Paul Bisaromay have pulled off his biggest merger ever last year, but $8.66 million in compensation still didn't qualify him for our ranking.

Then, we pulled out Valeant's proxy statement. And while CEO Michael Pearson didn't earn enough in 2012 to make the cutoff--his compensation just surpassed $6 million--he should have been at the top of the list last year. Pearson's 2011 pay package broke $36 million. He collected more than $18 million in stock and option awards, plus a special $13.7 million dividend payment, stemming from agreements negotiated years before.

We hate to miss a scoop. Naturally. So, we vowed to avoid making the same mistake this time around. Rather than limit our executive-pay search to the biggest pharma companies and biotechs, plus the usual suspects who often make CEO-pay rankings, we used a bigger net. We collected compensation information from 50 companies, including numbers for CEOs, CFOs, R&D chiefs and other top executives.

Partly because of this search, but mostly because of big bonuses and awards at fast-growing Regeneron ($REGN), we have a brand-new No. 1 on our list. That's Regeneron CEO Leonard Schleifer, whose 2012 compensation totaled $30.047 million. You'll notice some other newbies, such as Leonard Bell from Alexion ($ALXN), whose pay bump put him in 12th place. And then there are familiar faces, such as Pfizer ($PFE) CEO Ian Read; Johnson & Johnson's ($JNJ) former chairman and CEO, William Weldon; and Eli Lilly ($LLY) CEO John Lechleiter, who hung on in 10th place.

Many of the companies we researched pay their top people far less than the $10 million that served as our cutoff figure. Novo Nordisk ($NVO) CEO Lars Sorensen, who has presided over double-digit growth there for several years, collected a package of cash and stock awards worth about $5 million for 2012. GlaxoSmithKline ($GSK) CEO Andrew Witty made less than $6 million himself; he took a pay cut for the year because of Glaxo's shortfall on certain performance targets.
And then there are others who would have made the list, had their titles been different. There's Regeneron R&D chief George Yancopoulos, whose extraordinary $81 million in compensation shows how much the company appreciates its newly minted blockbuster, Eylea. There's Mylan Chairman Robert Coury, who used to be a fixture on our list until Heather Bresch took over as CEO; he made more than $28 million last year. Novartis' ($NVS) former chairman Daniel Vasella could have qualified for 12th place with his $13.98 million in compensation.

Vasella, then, gives us a quick segue to the ongoing debate over executive pay. In Switzerland, populist dismay at some high-profile compensation figures led to a public vote earlier this year. Citizens voted in new restrictions on common bonuses, such as golden parachutes, and gave shareholders a binding vote on executive pay. And local analysts figure that late-breaking news of Vasella's behind-the-scenes noncompete agreement--worth some $78 million over 5 years--helped pay activists to get out the vote. (Vasella ended up refusing the deal, by the way.)

In the U.S., where executives are paid more than anywhere else in the world, shareholders at some companies have successfully lobbied for a greater emphasis on performance pay and against extraordinary bonuses, such as change-in-control payments that send top executives on their way with tens of millions after a merger. Other companies have instituted "say-on-pay" advisory votes for shareholders, but those often end up as rubber stamps for the status quo.

Now, we're interested in what you have to say about executive compensation. Are the CEOs on this list worth their price? What's a supersuccessful new drug worth? Should CEO pay be docked for R&D failures? What about failed launches? Should other, lower-paid executives earn more? Tweet your opinions to @FiercePharma using the hashtag #FPexecpay, leave your comments below or email us. We'll collect your thoughts in a future article.

As always, feel free to send us your thoughts on our coverage. And if we missed a well-paid CEO, be sure to let us know.

-- Tracy Staton (email | Twitter)

For more:
Top 10 Biotech CEO Pay Packages of 2012
Top 10 Pharma CEO salaries of 2010
Top 10 Pharma CEO salaries of 2009
2012's 10 highest-paid Med Tech CEOs
Top 10 Medical Device Industry CEO Salaries for 2011
Thank You Fierce Pharma and Ms Staton.